Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL130950 | 0.80 | L3MBTL3 (0.33) | L3MBTL3L3MBTL1TSHRCASP1KDM4E | |
| SCHEMBL13497277 | 0.80 | L3MBTL3 (0.33) | L3MBTL3L3MBTL1TSHRCASP1KDM4E | |
| SCHEMBL6923393 | 0.79 | CHRNA7 (0.34) | L3MBTL3L3MBTL1TSHRCASP1 | |
| SCHEMBL15320526 | 0.79 | CHRNA7 (0.34) | L3MBTL3L3MBTL1TSHRCASP1 | |
| SCHEMBL11337191 | 0.78 | CHRNA7 (0.32) | — | |
| SCHEMBL6922726 | 0.77 | HTR6 (0.36) | L3MBTL3L3MBTL1TSHRCASP1 | |
| SCHEMBL2050198 | 0.77 | HTR6 (0.36) | L3MBTL3L3MBTL1TSHRCASP1 | |
| SCHEMBL2050194 | 0.77 | HTR6 (0.36) | L3MBTL3L3MBTL1TSHRCASP1 | |
| SCHEMBL131443 | 0.76 | CHRNA7 (0.50) | TSHRCASP1HRH3 | |
| SCHEMBL131067 | 0.74 | SMN1; SMN2 (0.44) | SMN1; SMN2L3MBTL3L3MBTL1HRH3OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120058999-A1 | Substituted Tetrahydropyrrolopyrazine Compounds | GRUENENTHAL GMBH (DE) | 2012-03-08 | — | — | US | disclosed |
| US-20120058999-A1 | Substituted Tetrahydropyrrolopyrazine Compounds | GRUENENTHAL GMBH (DE) | 2012-03-08 | — | — | US | disclosed |
| WO-2012028331-A1 | SUBSTITUTED TETRAHYDROPYRROLOPYRAZINE DERIVATIVES | Grünenthal GmbH (DE) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058999-A1 | Substituted Tetrahydropyrrolopyrazine Compounds | BDKRB1, BDKRB2, LTB4R | SMN1; SMN2 2489/4885L3MBTL3 4558/4885L3MBTL1 4265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.